ERBB2 and breast carcinoma: Containing a tubulin inhibitor payload, ARX788 has been shown to be well‐tolerated in the ACE‐Breast01 study among patients with metastatic HER2+ breast cancer, with AEs primarily of grades 1–2 [48, 49].